Vistagen Therapeutics, Inc. (VTGN)
NASDAQ: VTGN · Real-Time Price · USD
4.330
+0.050 (1.17%)
At close: Dec 5, 2025, 4:00 PM EST
4.380
+0.050 (1.15%)
After-hours: Dec 5, 2025, 7:48 PM EST
Vistagen Therapeutics Employees
As of March 31, 2025, Vistagen Therapeutics had 57 total employees, including 56 full-time and 1 part-time employees. The number of employees increased by 17 or 42.50% compared to the previous year.
Employees
57
Change (1Y)
17
Growth (1Y)
42.50%
Revenue / Employee
$12,649
Profits / Employee
-$1,091,860
Market Cap
171.02M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VTGN News
- 4 days ago - Vistagen Appoints Nick Tressler as Chief Financial Officer - Business Wire
- 9 days ago - Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting - Business Wire
- 17 days ago - Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 - Seeking Alpha
- 22 days ago - Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update - Business Wire
- 25 days ago - Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025 - Business Wire
- 4 weeks ago - Vistagen to Participate in Stifel Healthcare Conference 2025 - Business Wire
- 4 weeks ago - Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder - Business Wire